<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week&apos;s episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we&apos;re speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of keeping development, financing, and hiring in sync as biotech companies grow, his experiences surviving near-death cash deficits, the importance of investing early in CMC, and what to expect in 2026.  Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;On this week&amp;apos;s episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we&amp;apos;re speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of keeping development, financing, and hiring in sync as biotech companies grow, his experiences surviving near-death cash deficits, the importance of investing early in CMC, and what to expect in 2026.  &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders. Cooper talks about the importance of ke...

BoB@JPM: Ron Cooper, enGene

<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>The Business of Biotech was back in San Francisco for the J.P. Morgan Healthcare Conference (January 12 - 15) and this week we sit down with Marc Salzberg, M.D., CEO, CMO, and Board Chair at Airway Therapeutics, a company developing a recombinant version of human surfactant protein D for several respiratory, inflammatory, and infectious diseases including bronchopulmonary dysplasia (BPD), which is currently in Phase 2b/3 trials. Brian talks about why he selected BPD as a lead clinical indication (a disease primarily affecting preterm infants), what he learned through founding and selling a CRO, how a private biotech funds a pivotal trial across continents, and offers an industry outlook for 2026.   Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;The Business of Biotech was back in San Francisco for the J.P. Morgan Healthcare Conference (January 12 - 15) and this week we sit down with Marc Salzberg, M.D., CEO, CMO, and Board Chair at Airway Therapeutics, a company developing a recombinant version of human surfactant protein D for several respiratory, inflammatory, and infectious diseases including bronchopulmonary dysplasia (BPD), which is currently in Phase 2b/3 trials. Brian talks about why he selected BPD as a lead clinical indication (a disease primarily affecting preterm infants), what he learned through founding and selling a CRO, how a private biotech funds a pivotal trial across continents, and offers an industry outlook for 2026.   &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  The Business of Biotech was back in San Francisco for the J.P. Morgan Healthcare Conference (January 12 - 15) and this week we sit down with Marc Salzberg, M.D., CEO, CMO, and Board Chair at Airway Therapeutics, a company developing a recombinant version of human surfactant protein D for several respiratory, inflammatory, and infectious diseases including bronchopulmonary dysplasia (BPD), which is currently in Phase 2b/3 trials. Brian ta...

BoB@JPM: Marc Salzberg, M.D., Airway Therapeutics 

<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week&apos;s episode of the Business of Biotech, we&apos;re speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene), J&amp;J, Merck, Daiichi Sankyo, and GSK. Ken talks about Zymeworks&apos; shift to a royalty model for development funding and value creation, lessons learned from platform deals and cross-border R&amp;D, the benefits of strong royalty agreements and backloaded milestone payments over headline upfronts, and industry dynamics for the coming year. Ken also shares insights from his deep experiences as a biotech investor and corporate director, and explains why scientific primacy should always drive biotech business decisions.         Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;On this week&amp;apos;s episode of the Business of Biotech, we&amp;apos;re speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene), J&amp;amp;J, Merck, Daiichi Sankyo, and GSK. Ken talks about Zymeworks&amp;apos; shift to a royalty model for development funding and value creation, lessons learned from platform deals and cross-border R&amp;amp;D, the benefits of strong royalty agreements and backloaded milestone payments over headline upfronts, and industry dynamics for the coming year. Ken also shares insights from his deep experiences as a biotech investor and corporate director, and explains why scientific primacy should always drive biotech business decisions.         &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene), J&amp;J, Merck, Daiichi Sankyo, and GSK. Ken talks about Zymeworks' shift to a royalty model for development funding and value creation, lessons learn...

A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith

<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>This week&apos;s special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and reporting that mattered most in 2025, and what each editor has planned for 2026. From the RNA, cell, and gene therapy space to small molecule manufacturing, bioprocessing, drug discovery, and outsourcing, the editors weigh in on key industry trends, new developments, and policy surprises from their respective coverage areas. Topics include biotech funding dynamics, FDA leadership, China&apos;s growing role, favorite holiday movies, and much, much more. Special thanks to Tyler Menichiello and the Better Biopharma podcast for hosting this roundtable discussion. Happy New Year!     Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;This week&amp;apos;s special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and reporting that mattered most in 2025, and what each editor has planned for 2026. From the RNA, cell, and gene therapy space to small molecule manufacturing, bioprocessing, drug discovery, and outsourcing, the editors weigh in on key industry trends, new developments, and policy surprises from their respective coverage areas. Topics include biotech funding dynamics, FDA leadership, China&amp;apos;s growing role, favorite holiday movies, and much, much more. Special thanks to Tyler Menichiello and the Better Biopharma podcast for hosting this roundtable discussion. Happy New Year!     &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  This week's special holiday episode of the Business of Biotech brings seven chief editors from the Life Science Connect family together to talk about the life sciences industry topics, trips, and reporting that mattered most in 2025, and what each editor has planned for 2026. From the RNA, cell, and gene therapy space to small molecule manufacturing, bioprocessing, drug discovery, and outsourcing, the editors weigh in on key industry tre...

Life Science Connect Editors' Roundtable: Wrapping Up 2025 And Looking Ahead

<a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms">We love to hear from our listeners. Send us a message. </a>On this week&apos;s episode of the Business of Biotech, Nick Manusos, CEO at Kenai Therapeutics, talks about his experiences building cell therapy spinouts from FujiFilm Cellular Dynamics, learning from big pharma decision-making processes, and dosing the first patient with Kenai&apos;s allogeneic neuron replacement cell therapy for Parkinson&apos;s disease. Nick also talks about funding an early-stage cell therapy company and forging key manufacturing and therapy administration partnerships. Access this and hundreds of episodes of the Business of Biotech videocast under the <a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'>Business of Biotech</a> tab at lifescienceleader.com. Subscribe to our monthly <a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'>Business of Biotech newsletter</a>. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: <a href='https://www.linkedin.com/in/bencomer/'>https://www.linkedin.com/in/bencomer/</a>

<description>&lt;p&gt;&lt;a target="_blank" href="https://www.buzzsprout.com/twilio/text_messages/1011661/open_sms"&gt;We love to hear from our listeners. Send us a message. &lt;/a&gt;&lt;/p&gt;&lt;p&gt;On this week&amp;apos;s episode of the Business of Biotech, Nick Manusos, CEO at Kenai Therapeutics, talks about his experiences building cell therapy spinouts from FujiFilm Cellular Dynamics, learning from big pharma decision-making processes, and dosing the first patient with Kenai&amp;apos;s allogeneic neuron replacement cell therapy for Parkinson&amp;apos;s disease. Nick also talks about funding an early-stage cell therapy company and forging key manufacturing and therapy administration partnerships. &lt;/p&gt;&lt;p&gt;Access this and hundreds of episodes of the &lt;b&gt;Business of Biotech videocast&lt;/b&gt; under the &lt;a href='https://www.lifescienceleader.com/solution/the-business-of-biotech-podcast-lsl'&gt;&lt;b&gt;Business of Biotech&lt;/b&gt;&lt;/a&gt; tab at lifescienceleader.com. &lt;/p&gt; &lt;p&gt;Subscribe to our monthly &lt;a href='https://www9.lifescienceleader.com/business-of-biotech-nl-sign-up/'&gt;&lt;b&gt;Business of Biotech newsletter&lt;/b&gt;&lt;/a&gt;.&lt;br/&gt; &lt;br/&gt;Get in touch with &lt;b&gt;guest and topic suggestions&lt;/b&gt;: ben.comer@lifescienceleader.com&lt;br/&gt;&lt;br/&gt;Find &lt;b&gt;Ben Comer&lt;/b&gt; &lt;b&gt;on LinkedIn&lt;/b&gt;: &lt;a href='https://www.linkedin.com/in/bencomer/'&gt;https://www.linkedin.com/in/bencomer/&lt;/a&gt;&lt;br/&gt;&lt;br/&gt;&lt;br/&gt;&lt;/p&gt;</description>

We love to hear from our listeners. Send us a message.  On this week's episode of the Business of Biotech, Nick Manusos, CEO at Kenai Therapeutics, talks about his experiences building cell therapy spinouts from FujiFilm Cellular Dynamics, learning from big pharma decision-making processes, and dosing the first patient with Kenai's allogeneic neuron replacement cell therapy for Parkinson's disease. Nick also talks about funding an early-stage cell therapy company and forging key manufacturing...

Building Cell Therapy Companies With Kenai Therapeutics' Nick Manusos 

The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.

Business Of Biotech

Details

Recent Episodes